An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

A growing number of obese adults and children have been prescribed Ozempic or similar medications to lose weight ...

Despite their benefits, there are a number of things to consider before taking weight loss drugs – including possible ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

Discover how Ozempic is transforming America's eating, shopping, and dressing habits, with insights from Dr. Alexandra Sowa's ...

Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most ...